Evofem Biosciences

Evofem Biosciences is a biopharmaceutical company focused on women's sexual and reproductive health. The company has developed Phexxi, a hormone-free vaginal gel that is the first of its kind approved in the United States for the prevention of pregnancy. Additionally, Evofem is working on EVO100, a vaginal pH regulator designed to prevent the transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Headquartered in San Diego, California, Evofem aims to address unmet needs in the field of women’s health through innovative products.

Ivy Zhang

CFO and Secretary

1 past transactions

Neothetics

Acquisition in 2018
Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.